Danger of Multiple Emergency room visits to different Hospitals
Posted by: admin on: July 25, 2011
If you want to stay safe and receive quality medical care while you’re in the ER, its best if you visit the same (Emergency Rooms) ER each time.
- A report published released recently in the Archives of Internal Medicine showed that adults who made multiple ER trips to separate hospitals — some upwards of five — created a host of dangerous and costly problems because full health information is not always shared between hospitals.
- The reasons for choosing different facilities varied, sometimes patients moved or changed insurance between visits, while others got transferred between facilities.
- Patients who visited multiple ERs were exposed to the risk of medical errors, adverse events, delays in their treatment while waiting for more information and duplication of testing which added costs.
- Patients who visited more than two different sites racked up nearly twice the bill compared with patients who went to the same sites.
- The government has invested tens of millions of dollars to help providers implement electronic medical records systems.
- Until all providers get on board and install and use these devices, patients will continue to be at risk, not only in the ER, but doctors’ offices and hospitals as well, and we will receive poor, expensive health care.
Read More on http://www.kevinmd.com/blog/2011/03/danger-multiple-emergency-room-visits-hospitals.html
Menopause and cancer: What women should know
Posted by: admin on: July 22, 2011
Menopause often brings more than physical changes. It also may bring uncertainty about cancer risks and cancer prevention.
How does menopause affect a woman’s cancer risk?
Menopause does not cause cancer. But your risk of developing cancer increases as you age. So women going through menopause have a greater chance of developing cancer because they’re older.
How does the age at which a woman starts menopause affect her cancer risk?
Starting menopause after age 55 increases a woman’s risk of breast cancer and endometrial cancer. That’s probably because she’s been exposed to more estrogen. During a woman’s menstrual cycle, estrogen stimulates the uterus and breast tissue. So the more menstrual periods a woman has, the longer these tissues are exposed to estrogen.
Women who start menopause later also may have an increased risk of ovarian cancer possibly because they have had more ovulations.
How PCOS can be diagnosed and treated in primary care
Posted by: admin on: July 22, 2011
It is one of the most common causes of dysfunctional uterine bleeding, with a complaint of irregular periods being the most common presenting complaint to the doctor. The PCOS diagnostic criteria were developed by the National Institute of Health (NIH) in 1990, and include the following:
1. Hyperandrogenism: These women tend to have more androgen (the classic male sex hormones) levels floating around in their system, causing hirsutism, acne, male pattern hair loss (alopecia), and elevated blood testostosterone levels.
2. Chronic Anovulation: These women tend to ovulate less, and therefore exhibit more difficulty with their periods. They may lack periods all together (Amenorrhea), have cycles that last greater than 35 days (Oligomenorrhea), have unpredictable periods (Dysfunctional Uterine Bleeding), or report of infertility with difficulty reaching pregnancy.
3. All secondary causes of the above must be ruled out: Pregnancy, Thyroid Disease, Eating Disorders, Exercise Related Amenorrhea, Hypothalamic-Pituitary Disorder, Premature Ovarian Failure, Pituitary Adenoma, Congenital Adrenal Hyperplasia, and Cushing’s disease.
Anti obesity drug Sibutramine withdrawn from US markets due to adverse cardiovascular risk
Posted by: admin on: July 22, 2011
- Abbott Laboratories has withdrawn the obesity drug Sibutramine (Meridia) from the market in light of clinical trial data pointing to an increased risk for stroke and myocardial infarction, the US Food and Drug Administration (FDA) announced.
- The agency asked Abbott Laboratories to pull the drug from the market after it evaluated data from a post marketing study of the drug’s cardiovascular safety. The study, called the Sibutramine Cardiovascular Outcomes Trial (SCOUT), demonstrated a 16% increase in the risk for serious cardiovascular events such as nonfatal heart attack, nonfatal stroke, the need for resuscitation after the heart stopped, and death in a cohort of patients given Sibutramine compared with another given a placebo..
- The FDA is advising physicians to stop prescribing Sibutramine and for patients to stop taking it and talk to their healthcare provider about alternative weight-loss regimens. Dr. Jenkins also said he is not aware of any long-term consequences for patients who stop taking the drug. The cardiovascular events observed in SCOUT, he said, probably stem from Sibutramine increasing blood pressure and heart rate. These adverse effects disappear once the drug is withdrawn.
Read more at http://www.medscape.org/viewarticle/730515?src=cmemp
Search
- drchasrani: Difficult to get such a data, authenticated at that. Try Times of India online library
- rakesh pore: hi, where can i get genuine information about "10 most common drugs sold in india?" i want it for a local project
- nilesh dutta: sir, Plz give detail about MBA Sports Management Thanks and Regards
